Mitchell Mcleod Pugh & Williams Inc. continued to hold its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,746 shares of the biopharmaceutical company’s stock at the end of the second quarter. Mitchell Mcleod Pugh & Williams Inc.’s holdings in Gilead Sciences were worth $831,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of the company. Norges Bank bought a new position in shares of Gilead Sciences during the fourth quarter worth about $997,048,000. Parnassus Investments CA boosted its position in shares of Gilead Sciences by 37.4% in the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after buying an additional 4,556,901 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Gilead Sciences by 9.8% in the first quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock worth $2,076,368,000 after buying an additional 2,727,063 shares during the last quarter. Numeric Investors LLC boosted its position in shares of Gilead Sciences by 173.5% in the fourth quarter. Numeric Investors LLC now owns 2,820,505 shares of the biopharmaceutical company’s stock worth $201,976,000 after buying an additional 1,789,101 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its position in shares of Gilead Sciences by 75.0% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,549,292 shares of the biopharmaceutical company’s stock worth $173,148,000 after buying an additional 1,092,206 shares during the last quarter. 74.06% of the stock is owned by institutional investors and hedge funds.
Gilead Sciences, Inc. (GILD) traded down 0.85% during mid-day trading on Friday, hitting $72.08. The company’s stock had a trading volume of 3,665,210 shares. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $82.10. The firm has a market cap of $94.13 billion, a price-to-earnings ratio of 7.83 and a beta of 1.21. The firm has a 50 day moving average of $72.31 and a 200-day moving average of $68.76.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same quarter last year, the business posted $3.08 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post $8.76 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.86%. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.
WARNING: This report was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://stocknewstimes.com/2017/08/11/mitchell-mcleod-pugh-williams-inc-holds-stake-in-gilead-sciences-inc-nasdaqgild.html.
A number of equities research analysts recently commented on GILD shares. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $74.58 price target on the stock in a research report on Tuesday, April 18th. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 price target on the stock in a research report on Tuesday, May 2nd. BidaskClub upgraded Gilead Sciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Barclays PLC restated an “overweight” rating and set a $85.00 price target (down from $90.00) on shares of Gilead Sciences in a research report on Sunday, April 23rd. Finally, Credit Suisse Group restated an “outperform” rating and set a $79.00 price target on shares of Gilead Sciences in a research report on Monday, May 15th. Twelve research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Gilead Sciences presently has an average rating of “Buy” and a consensus target price of $80.31.
In other Gilead Sciences news, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.06, for a total value of $355,300.00. Following the completion of the sale, the executive vice president now owns 102,988 shares in the company, valued at approximately $7,318,327.28. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The disclosure for this sale can be found here. In the last quarter, insiders sold 206,666 shares of company stock valued at $15,223,184. Company insiders own 1.30% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
